Clario Acquisition Boosts Thermo Fisher to Q1 Revenue and EPS Beat
Summary
Thermo Fisher Scientific reported strong Q1 results, with revenue reaching $11.01 billion and adjusted EPS of $5.44, both surpassing analyst expectations. Revenue grew 6% year-over-year, and adjusted EPS also increased by 6%. These positive results were significantly bolstered by the recently completed Clario acquisition, which was previously detailed in the company's 2025 10-K filing on February 26, 2026. The successful integration and contribution of this major acquisition to the company's top-line performance is a key positive takeaway for investors. The company also repurchased $3.0 billion of stock during the quarter. Traders will now focus on the updated 2026 financial guidance expected during the upcoming earnings conference call.
At the time of this announcement, TMO was trading at $501.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $191B. The 52-week trading range was $385.46 to $643.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.